Skip to main content

Cooper Ronald Harold Wilfred's Form 4/A amendment

Amended

Albireo Pharma, Inc. (ALBO) · filed Jan 9, 2023

Accession no.
0001209191-23-002632
Filed
Jan 9, 2023
Trade date
Oct 24, 2022
Filing delay
77 days
Rule 10b5-1 plan
Not on the form (before 2023)
Original filed
Oct 25, 2022

This filing lists 1 non-derivative transaction. Open-market sales total $18.0K. It was filed 77 days after the trade.

This amendment replaces 0001209191-22-054485 (filed Oct 25, 2022).

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Cooper Ronald Harold WilfredCIK 0001676880Director, Officer (President and CEO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Oct 24, 2022Common StockSSaleDisposed−919$19.58−$17,994.0258,501Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.

F2

Represents 31,106 shares of common stock and 27,395 restricted stock units. Includes 534 shares of common stock acquired under the Albireo Pharma, Inc. 2018 Employee Stock Purchase Plan (the "ESPP") on May 31, 2019; 483 shares of common stock acquired under the ESPP on November 30, 2019; 1,205 shares of common stock acquired under the ESPP on May 31, 2020; and 818 shares of common stock acquired under the ESPP on May 31, 2021.

Remarks

This amended Form 4 is being filed solely to report the acquisition of an aggregate of 3,040 additional shares of common stock under the ESPP on May 31, 2019, November 30, 2019, May 31, 2020 and May 31, 2021, as described in footnote 2 above.

Read the full filing on SEC EDGAR (opens in a new tab)